Skip to main content

Table 1 The demographic and clinicopathological parameters between training group and validation group

From: DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer

 

N

Training group

Test group

p Value

Total, n

465

233(50.1%)

232(49.9%)

 

Mean age, y

 

59.61 ± 11.03

59.84 ± 11.54

0.822

Stage

0.939

 I

12(2.6%)

7(3.0%)

5(2.2%)

 

 II

17(3.7%)

8(3.4%)

9(3.9%)

 

 III

369(79.4%)

185(79.4%)

184(79.3%)

 

 IV

67(14.4%)

33(14.2%)

34(14.7%)

 

Primary therapy outcome

0.773

 Complete remission

270(58.1%)

140(60.1%)

130(56.0%)

 

 Partial remission

51(11.0%)

25(10.7%)

26(11.2%)

 

 Progressive disease

32(6.9%)

14(6.0%)

18(7.8%)

 

 Stable disease

27(5.8%)

15(6.4%)

12(5.2%)

 

 Unknown

85(18.3%)

39(16.7%)

46(19.8%)

 

Tumour residual

0.894

 No macroscopic disease

100(21.5%)

50(21.5%)

50(21.6%)

 

 1–10 mm

209(44.9%)

100(42.9%)

109(47.0%)

 

 11–20 mm

28(6.0%)

15(6.4%)

13(5.6%)

 

 > 20 mm

89(19.1%)

48(20.6%)

41(17.7%)

 

 Unknown

39(8.4%)

20(8.6%)

19(8.2%)

 

Venous invasion

0.296

 No

53(11.4%)

29(12.4%)

24(10.3%)

 

 Yes

72(15.5%)

41(17.6%)

31(13.4%)

 

 Unknown

340(73.1%)

163(70.0%)

177(76.3%)

 

Survival status

0.365

 Alive

188(40.4%)

99(42.5%)

89(38.4%)

 

 Dead

277(59.6%)

134(57.5%)

143(61.6%)

 

Lymphatic invasion

0.795

 No

62(13.3%)

33(14.2%)

29(12.5%)

 

 Yes

117(25.2%)

60(25.8%)

57(24.6%)

 

 Unknown

286(61.5%)

140(60.1%)

146(62.9%)

Â